Presidio Pharmaceuticals aims to discover and advance potent antiviral drug candidates that can be taken orally once daily and combined with other HCV antivirals to combat viral resistance. With a pipeline targeting both NS5A and NS5B proteins of HCV, the company is well-positioned to compete in the growing HCV therapy market. Presidio has raised over $27 million in financing from various investors, including Panorama Capital and Baker Brothers Investments, to support its research and development efforts in viral infections, including HCV and HIV.